Study Comparing Negative Pressure Dressing vs Conventional in Patients With Resected STS After Radiotherapy
- Sponsor
- Centre Leon Berard
- Study ID
- NCT05944913
- Status
- Recruiting
Conditions
- Soft Tissue Sarcoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Prevena — DEVICEPREVENA™ is a CE-marked class IIa medical device. The PREVENA™ Incision Management System is also intended to manage the environment of closed surgical incisions and surround intact skin in patients at risk for developing post-operative complications, such as infection, by maintaining a closed environment via the application of a negative pressure wound therapy system to the incision.
Study Details
This is a randomized (1:1 ratio), prospective, comparative, controlled, open-label study. The aim is to compare the efficacy of negative pressure therapy (PREVENA™) versus standard postoperative wound management on the wound healing after surgery for previously irradiated Soft Tissue Sarcoma (STS)
Key Dates
- First listed
- Jul 13, 2023
- Start date
- Aug 3, 2023
- Status verified
- Aug 2025
- Primary completion
- Aug 31, 2026
- Completion
- Nov 30, 2026
Study Design
- Enrollment
- 166 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Experimental: Arm A : Surgery for STS and prevenaThe surgery for the STS lesion will be performed according to standard practices. PREVENA™ Incision Management System should be applied immediately post-surgery to clean surgically closed wounds. It should be continuously applied for a minimum of 2 days and up to a maximum of 7 days (as per PREVENA user manual)
- No Intervention: Arm B : Surgery for STS and standard postoperative wound managementThe surgery for the STS lesion will be performed according to standard practices. The dressing and drainage of the wound will be performed according to usual practices, with the exception of negative pressure dressings.
Primary Outcome Measure
The efficacy of negative pressure therapy (PREVENA) versus standard postoperative wound management on the wound healing after surgery for previously irradiated STS [ Time Frame: Within the 3-month postoperative period. ]
Central Contacts
- François Gouin, MD, Chirurgien0469855311
- Séverine METZGER, Project Manager0478782786
Related Studies
- LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic OncologyPHASE4 · Enrolling By Invitation · Massachusetts General Hospital · Los Angeles, California
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway AlterationPHASE2 · Recruiting · Medical College of Wisconsin · Jacksonville, Florida
- Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue SarcomaPHASE1/PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)PHASE1 · Recruiting · St. Jude Children's Research Hospital · Memphis, Tennessee